New research published in JAMA Network Open “raises doubt” about a major U.S. Centers for Medicare & Medicaid Services (CMS) justification for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third, the study’s authors say.
Yufei Li, a data analyst at VA Boston Healthcare System, and Susan Xu, senior director at McDermott+Consulting, said they found “no statistically significant difference in Medicare Part B drug spending between 340B hospitals and non-340B hospital” after controlling for differences in patient population and hospital characteristics. Their report was published online on Feb. 18.
New research published in JAMA Network Open “raises doubt” about a major U.S. Centers for Medicare & Medicaid Services (CMS) justification for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third, the study’s authors say.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
